Moneycontrol PRO
HomeNewsBusinessDr Reddy's launches generic product in US to treat gastroesophageal reflux disease

Dr Reddy's launches generic product in US to treat gastroesophageal reflux disease

Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.

October 20, 2020 / 16:19 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Dr Reddy’s Laboratories on Tuesday said it has launched over-the-counter (OTC) drug Famotidine tablets, used to treat gastroesophageal reflux disease, in the American market.

    "The company has launched the product, which is equivalent to Johnson & Johnson’s Pepcid AC, in the US after getting approval from the US Food and Drug Administration (USFDA)," Dr Reddy’s Laboratories said in a statement.

    Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.

    "This launch will help us fulfil an important therapy gap created in antacids market due to Ranitidine withdrawal,” Dr Reddy’s Laboratories North America Generics CEO Marc Kikuchi said.

    The Pepcid AC brand and generic versions had US sales of around $211 million for the 12 months ended in August 2020.

    PTI
    first published: Oct 20, 2020 04:18 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseOutskill Genai